Skip to main content

Arcturus Therapeutics Ltd. (NASDAQ: ARCT) Leading the Way in Wednesday Trading Based on Percentage Gain

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is one of today’s top gainers. The company’s shares are currently up 25.94% on the day to $19.52.

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company’s development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs.

So far today, approximately 3.68M shares of Arcturus Therapeutics Holdings Inc. have been exchanged, as compared to an average 30-day volume of 284.9k shares.

Arcturus Therapeutics Holdings Inc. share prices have moved between a 52-week high of $31.41 and a 52-week low of $11.7. The stock has moved 2.51% over the past week.

To learn more about Arcturus Therapeutics Holdings Inc., visit the company’s website at

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN

IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published:


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.